Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: A double-blind extension of a Phase III randomized controlled trial - Roden, M; Merker, L; Christiansen, A V; Roux, F; Salsali, A; Kim, G; Stella, P; Woerle, H J; Broedl, U C (Cardiovasc Diabetol, 2015)